Cargando…
HIV medication-based urolithiasis
Drug-induced renal calculi represent 1–2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, espe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377784/ https://www.ncbi.nlm.nih.gov/pubmed/25852859 http://dx.doi.org/10.1093/ckj/sfu008 |
_version_ | 1782363958388195328 |
---|---|
author | Izzedine, Hassane Lescure, François Xavier Bonnet, Fabrice |
author_facet | Izzedine, Hassane Lescure, François Xavier Bonnet, Fabrice |
author_sort | Izzedine, Hassane |
collection | PubMed |
description | Drug-induced renal calculi represent 1–2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, especially indinavir and atazanavir, and more recently darunavir. Urolithiasis attributable to other PIs has also been reported in clinical cases such as those during non-PI use. Antiretroviral drug-induced calculi deserve consideration because most of them are potentially preventable. This article summarizes the diagnosis, epidemiology, prevention and management of antiretroviral drug-induced urolithiasis. |
format | Online Article Text |
id | pubmed-4377784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43777842015-04-07 HIV medication-based urolithiasis Izzedine, Hassane Lescure, François Xavier Bonnet, Fabrice Clin Kidney J Original Contributions Drug-induced renal calculi represent 1–2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, especially indinavir and atazanavir, and more recently darunavir. Urolithiasis attributable to other PIs has also been reported in clinical cases such as those during non-PI use. Antiretroviral drug-induced calculi deserve consideration because most of them are potentially preventable. This article summarizes the diagnosis, epidemiology, prevention and management of antiretroviral drug-induced urolithiasis. Oxford University Press 2014-04 2014-03-11 /pmc/articles/PMC4377784/ /pubmed/25852859 http://dx.doi.org/10.1093/ckj/sfu008 Text en © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please email: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Contributions Izzedine, Hassane Lescure, François Xavier Bonnet, Fabrice HIV medication-based urolithiasis |
title | HIV medication-based urolithiasis |
title_full | HIV medication-based urolithiasis |
title_fullStr | HIV medication-based urolithiasis |
title_full_unstemmed | HIV medication-based urolithiasis |
title_short | HIV medication-based urolithiasis |
title_sort | hiv medication-based urolithiasis |
topic | Original Contributions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377784/ https://www.ncbi.nlm.nih.gov/pubmed/25852859 http://dx.doi.org/10.1093/ckj/sfu008 |
work_keys_str_mv | AT izzedinehassane hivmedicationbasedurolithiasis AT lescurefrancoisxavier hivmedicationbasedurolithiasis AT bonnetfabrice hivmedicationbasedurolithiasis |